- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04446026
A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen
June 7, 2021 updated by: Yonsei University
This is a randomized, placebo-controlled clinical trial of Teneligliptin as quadruple oral combination therapy for type 2 diabetes after failure of an oral triple anti-diabetic regimen.
Patients with uncontrolled type 2 diabetes (7.1% ≤ HbA1c ≤ 9%) prescribed with triple combination of oral antidiabetic drugs more than 12 weeks with sufficient doses (metformin >= 1000mg/d, Glimepiride >=4 mg/day, Gliclazide >= 60 mg/day, SGLT-2 inhibitor with approved dose by Korea FDA) will be included.
Using randomization, patients would take either teneligliptin (20mg) or placebo for 12 weeks.
After 12 weeks of trial, all patients would receive teneligliptin for another 12 weeks.
As outcomes, changes in HbA1c and fasting plasma glucose at 12th and 24th weeks compared with at baseline, and proportions of patients who achieved a glycemic goal (HbA1c <=7%) at 12th and 24th weeks will be evaluated.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yonsei Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age over 18 years and less than 81 years
- Patients with type 2 diabetes prescribed with triple combination of oral antidiabetic drugs more than 12 weeks with sufficient doses (metformin >= 1000mg/d, Glimepiride >=4 mg/day, Gliclazide >= 60 mg/day, SGLT-2 inhibitor with approved dose by Korea FDA)
- Uncontrolled hyperglycemia with 7.1% ≤ HbA1c ≤ 9% at randomization period
- Recommended to use insulin by physicians
- Patients able to understand study protocol and cooperative
- Voluntary consent to participation of study after understanding study protocol
Exclusion Criteria:
- Type 1 diabetes, gestational diabetes, other than type 2 diabetes
- Insulin treatment more than 1 week (not necessarily continuous use) prior to screening visit within 1 year
- Hypersensitivity to TENELIA tablet including main and other component
- Use of DPP4 inhibitor more than 1 week prior to screening visit within 3 months or discontinuation of DPP4 inhibitor due to severe side effects regardless of treatment period
- History of acute or chronic metabolic acidosis and ketosis including diabetic ketoacidosis with/without comma prior to screening visit within 12 weeks
- Genetic trait of galactose intolerance, Lapp lactase deficiency, or glucose-galactose mal-absorption
- Difficulty in oral ingestion of drug owing to anatomical abnormalities in head and neck area, or owing to abnormalities in central nervous system
- Steroid use including per oral and non-oral more than 14 consecutive days prior to screening visit within 8 weeks (inhaled steroid use is permitted)
- Histories of any malignancy prior to screening visit within 5 years
- History of congestive heart failure (>= 10) NYHA class III)
- Uncontrolled arrhythmia, unstable angina, myocardial infarction, stroke, transient ischemic attack, cerebrovascular disease prior to screening visit within 24 weeks
- Initiation of statin to treat dyslipidemia prior to screening visit within 4 weeks or anticipated increasing dose of statin during study period
- Renal failure, chronic kidney disease stage <=3 (estimated glomerular filtration rate <30 mL/min/1.73 m2, calculated using EKD-EPI) or patients with dialysis
- Abnormalities in liver function test: AST, ALT, or ALP >= 2.5 fold of ULN or patients with liver cirrhosis (Child-Pugh class B or C)
- Infection of HIV, HBV, or HCV and patients subjected to anti-viral therapy within 1 year
- Pregnant or lactating women; or planning to be pregnant
- Patients with other severe infection or with severe injuries, or patients expecting any surgery with transient insulin use for peri-operational glucose control
- Alcohol or any psychotropic substances dependancy , or dependency of any unapproved substances
- Last visit of other clinical trials for treatment purposes prior to screening visit within 30 days
- Other inappropriate properties judged by researchers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
|
Experimental: teneligliptin
|
teneligliptin 20mg PO qd for 24weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hb1Ac
Time Frame: 12 weeks
|
Difference between baseline and HbA1c at 12 weeks after treatment with test drug
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: 24 weeks
|
Difference between baseline and HbA1c at 24 weeks after treatment with test drug
|
24 weeks
|
Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c)
Time Frame: 12 weeks
|
Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c) at 12 and 24 weeks after treatment with the test drug
|
12 weeks
|
Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c)
Time Frame: 24 weeks
|
Percentage of patients who reached target blood glucose (6.5% or 7% as HbA1c) at 12 and 24 weeks after treatment with the test drug
|
24 weeks
|
Fasting glucose
Time Frame: 12 weeks
|
Fasting blood glucose (FPG) at 12 and 24 weeks after treatment with test drug
|
12 weeks
|
Fasting glucose
Time Frame: 24 weeks
|
Fasting blood glucose (FPG) at 12 and 24 weeks after treatment with test drug
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 8, 2020
Primary Completion (Actual)
December 7, 2020
Study Completion (Actual)
May 17, 2021
Study Registration Dates
First Submitted
June 22, 2020
First Submitted That Met QC Criteria
June 22, 2020
First Posted (Actual)
June 24, 2020
Study Record Updates
Last Update Posted (Actual)
June 9, 2021
Last Update Submitted That Met QC Criteria
June 7, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2020-0488
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on teneligliptin
-
Handok Inc.Recruiting
-
Mitsubishi Tanabe Pharma CorporationCompletedType 2 Diabetes MellitusJapan
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Handok Inc.Recruiting
-
Mitsubishi Tanabe Pharma CorporationCompletedType 2 Diabetes MellitusChina
-
National Cerebral and Cardiovascular CenterRecruitingDiabetes Mellitus, Type 2Japan
-
Handok Inc.UnknownType 2 Diabetes MellitusKorea, Republic of
-
Handok Inc.Completed
-
Mitsubishi Tanabe Pharma CorporationCompleted